14 November 2017 - PHARMAC is seeking feedback on three proposals to widen funded access, from 1 January 2018, to various pharmaceuticals in the anti-infectives therapeutic group.

These are:

• Ledipasvir with sofosbuvir (Harvoni) for patients with chronic hepatitis C who have decompensated cirrhosis (Child-Pugh B or C), by removing a minimum MELD score requirement;
  
• Tenofovir disoproxil fumarate (Viread) for hepatitis B in women of childbearing age
  
• Paromomycin (Humatin) for Entamoeba histolytica intestinal colonisation
  

Read PHARMAC Consultation